Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon Oct 25, 2021 11:47am

189 Views

Post# 34045238

Arch Biopartners Historic Bought Financings

Dec 23, 2020 (One Placee)

announced it has closed the non-brokered private placement the Company disclosed in a press release December 23, 2020 (The “Offering”). Pursuant to the Offering, Arch issued 430,000 common shares priced at CAD $1.50 per common share (the “Common Shares”) for net proceeds of $500,000 USD (approximately $645,000 CAD) (the “Offering”).

June 30, 2020 (Two Placee)

The Company announced it closed a non-brokered private placement offering of 900,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross and net proceeds of up to $1,350,000 (the “Offering”).

Feb 2, 2018 (One Placee)

The Company announced it arranged a non-brokered private placement offering of up to 2,500,000 common shares priced at $0.50 per common share (the “Common Shares”) for gross proceeds of up to $1,250,000 (the “Offering”).

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity